SEC Form 4 · accession 0001209191-15-015509
INCYTE CORP · INCY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard S Levy
Officer — EVP, Chief Drug Dev&Medical Of
Period of report
Feb 17, 2015
Accepted (ET)
Feb 18, 2015 · 5:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 17, 2015 | M | 3,683 | $17.79 | A | 21,888 | D | |
| Common Stock | Feb 17, 2015 | M | 8,317 | $14.72 | A | 30,205 | D | |
| Common StockF1,F2,F3 | Feb 17, 2015 | S | 12,000 | $76.90 | D | 18,205 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $17.79 | Feb 17, 2015 | M | 3,683 | D | — | Jan 18, 2019 | Common Stock | 3,683 | 90,217 | D |
| Non-Qualified Stock Option (right to buy)F5 | $14.72 | Feb 17, 2015 | M | 8,317 | D | — | Jan 24, 2018 | Common Stock | 8,317 | 0 | D |
Explanation of responses
- F1Represents weighted average sale price. Actual sale prices ranged from $75.55 - $78.00.
- F2Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
- F3This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
- F4Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
- F5Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.